$VKTX Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Viking Therapeutics, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Viking Therapeutics, Inc.. Get notifications about new insider transactions in Viking Therapeutics, Inc. for free.
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 25 2021 | VKTX | Viking Therapeutic ... | FOEHR MATTHEW W | Director | Option Exercise | X | 1.50 | 20,000 | 30,000 | 0 | |
| Mar 25 2021 | VKTX | Viking Therapeutic ... | FOEHR MATTHEW W | Director | Buy | X | 1.50 | 20,000 | 30,000 | 46,250 | 26.3 K to 46.3 K (+76.19 %) |
| Mar 25 2021 | VKTX | Viking Therapeutic ... | FOEHR MATTHEW W | Director | Option Exercise | X | 1.50 | 20,000 | 30,000 | 0 | |
| Mar 25 2021 | VKTX | Viking Therapeutic ... | FOEHR MATTHEW W | Director | Buy | X | 1.50 | 20,000 | 30,000 | 46,250 | 26.3 K to 46.3 K (+76.19 %) |
| Jan 19 2021 | VKTX | Viking Therapeutic ... | ZANTE GREG | Chief Financial Off ... | Payment of Exercise | F | 6.68 | 808 | 5,397 | 89,751 | 90.6 K to 89.8 K (-0.89 %) |
| Jan 19 2021 | VKTX | Viking Therapeutic ... | Mancini Marianna | Chief Operating Off ... | Payment of Exercise | F | 6.68 | 994 | 6,640 | 169,952 | 170.9 K to 170 K (-0.58 %) |
| Jan 19 2021 | VKTX | Viking Therapeutic ... | Mancini Marianna | Chief Operating Off ... | Payment of Exercise | F | 6.48 | 686 | 4,445 | 170,946 | 171.6 K to 170.9 K (-0.40 %) |
| Jan 19 2021 | VKTX | Viking Therapeutic ... | MORNEAU MICHAEL | VP, Finance and Adm ... | Payment of Exercise | F | 6.68 | 1,685 | 11,256 | 116,062 | 117.7 K to 116.1 K (-1.43 %) |
| Jan 19 2021 | VKTX | Viking Therapeutic ... | Lian Brian | President & CEO | Payment of Exercise | F | 6.68 | 5,611 | 37,481 | 1,894,181 | 1.9 M to 1.9 M (-0.30 %) |
| Jan 06 2021 | VKTX | Viking Therapeutic ... | Rowland Charles A Jr | Director | Option Exercise | A | 5.80 | 22,000 | 127,600 | 22,000 | |
| Jan 06 2021 | VKTX | Viking Therapeutic ... | MACARTNEY LAWSON | Director | Option Exercise | A | 5.80 | 22,000 | 127,600 | 22,000 | |
| Jan 06 2021 | VKTX | Viking Therapeutic ... | Rouan Sarah Kathryn | Director | Option Exercise | A | 5.80 | 22,000 | 127,600 | 22,000 | |
| Jan 06 2021 | VKTX | Viking Therapeutic ... | MORNEAU MICHAEL | VP, Finance and Adm ... | Option Exercise | A | 5.80 | 33,000 | 191,400 | 33,000 | |
| Jan 06 2021 | VKTX | Viking Therapeutic ... | MORNEAU MICHAEL | VP, Finance and Adm ... | Payment of Exercise | F | 5.80 | 2,739 | 15,886 | 117,747 | 120.5 K to 117.7 K (-2.27 %) |
| Jan 06 2021 | VKTX | Viking Therapeutic ... | MORNEAU MICHAEL | VP, Finance and Adm ... | Grant | A | 0.00 | 6,667 | 0 | 120,486 | 113.8 K to 120.5 K (+5.86 %) |
| Jan 06 2021 | VKTX | Viking Therapeutic ... | MORNEAU MICHAEL | VP, Finance and Adm ... | Grant | A | 0.00 | 14,667 | 0 | 113,819 | 99.2 K to 113.8 K (+14.79 %) |
| Jan 06 2021 | VKTX | Viking Therapeutic ... | Lian Brian | President & CEO | Option Exercise | A | 5.80 | 369,000 | 2,140,200 | 369,000 | |
| Jan 06 2021 | VKTX | Viking Therapeutic ... | Lian Brian | President & CEO | Payment of Exercise | F | 5.80 | 16,973 | 98,443 | 1,899,792 | 1.9 M to 1.9 M (-0.89 %) |
| Jan 06 2021 | VKTX | Viking Therapeutic ... | Lian Brian | President & CEO | Grant | A | 0.00 | 40,333 | 0 | 1,916,765 | 1.9 M to 1.9 M (+2.15 %) |
| Jan 06 2021 | VKTX | Viking Therapeutic ... | Lian Brian | President & CEO | Grant | A | 0.00 | 164,000 | 0 | 1,876,432 | 1.7 M to 1.9 M (+9.58 %) |
| Jan 06 2021 | VKTX | Viking Therapeutic ... | Lian Brian | President & CEO | Payment of Exercise | F | 5.63 | 31,545 | 177,598 | 1,712,432 | 1.7 M to 1.7 M (-1.81 %) |
| Jan 06 2021 | VKTX | Viking Therapeutic ... | ZANTE GREG | Chief Financial Off ... | Option Exercise | A | 5.80 | 78,000 | 452,400 | 78,000 | |
| Jan 06 2021 | VKTX | Viking Therapeutic ... | ZANTE GREG | Chief Financial Off ... | Payment of Exercise | F | 5.80 | 2,787 | 16,165 | 90,559 | 93.3 K to 90.6 K (-2.99 %) |
| Jan 06 2021 | VKTX | Viking Therapeutic ... | ZANTE GREG | Chief Financial Off ... | Grant | A | 0.00 | 6,783 | 0 | 93,346 | 86.6 K to 93.3 K (+7.84 %) |
| Jan 06 2021 | VKTX | Viking Therapeutic ... | ZANTE GREG | Chief Financial Off ... | Grant | A | 0.00 | 64,667 | 0 | 86,563 | 21.9 K to 86.6 K (+295.34 %) |
| Jan 06 2021 | VKTX | Viking Therapeutic ... | Mancini Marianna | Chief Operating Off ... | Option Exercise | A | 5.80 | 90,000 | 522,000 | 90,000 | |
| Jan 06 2021 | VKTX | Viking Therapeutic ... | Mancini Marianna | Chief Operating Off ... | Payment of Exercise | F | 5.80 | 2,773 | 16,083 | 171,632 | 174.4 K to 171.6 K (-1.59 %) |
| Jan 06 2021 | VKTX | Viking Therapeutic ... | Mancini Marianna | Chief Operating Off ... | Grant | A | 0.00 | 6,750 | 0 | 174,405 | 167.7 K to 174.4 K (+4.03 %) |
| Jan 06 2021 | VKTX | Viking Therapeutic ... | Mancini Marianna | Chief Operating Off ... | Grant | A | 0.00 | 73,000 | 0 | 167,655 | 94.7 K to 167.7 K (+77.12 %) |
| Sep 16 2020 | VKTX | Viking Therapeutic ... | MORNEAU MICHAEL | VP, Finance and Adm ... | Payment of Exercise | F | 6.25 | 1,557 | 9,731 | 97,873 | 99.4 K to 97.9 K (-1.57 %) |
| Sep 16 2020 | VKTX | Viking Therapeutic ... | MORNEAU MICHAEL | VP, Finance and Adm ... | Grant | A | 0.00 | 4,500 | 0 | 99,430 | 94.9 K to 99.4 K (+4.74 %) |
| Sep 16 2020 | VKTX | Viking Therapeutic ... | Lian Brian | President & CEO | Payment of Exercise | F | 6.25 | 19,192 | 119,950 | 1,742,363 | 1.8 M to 1.7 M (-1.09 %) |
| Sep 16 2020 | VKTX | Viking Therapeutic ... | Lian Brian | President & CEO | Grant | A | 0.00 | 55,500 | 0 | 1,761,555 | 1.7 M to 1.8 M (+3.25 %) |
| Aug 27 2020 | VKTX | Viking Therapeutic ... | LIGAND PHARMACEUTICALS INC | 10% Owner | Sell | S | 8.11 | 94,488 | 766,109 | 5,819,383 | 5.9 M to 5.8 M (-1.60 %) |
| Aug 27 2020 | VKTX | Viking Therapeutic ... | LIGAND PHARMACEUTICALS INC | 10% Owner | Sell | S | 8.11 | 94,488 | 766,109 | 5,819,383 | 5.9 M to 5.8 M (-1.60 %) |
| Aug 27 2020 | VKTX | Viking Therapeutic ... | LIGAND PHARMACEUTICALS INC | 10% Owner | Sell | S | 8.02 | 70,000 | 561,575 | 5,968,083 | 6 M to 6 M (-1.16 %) |
| Aug 27 2020 | VKTX | Viking Therapeutic ... | LIGAND PHARMACEUTICALS INC | 10% Owner | Sell | S | 8.02 | 70,000 | 561,575 | 5,968,083 | 6 M to 6 M (-1.16 %) |
| Jun 30 2020 | VKTX | Viking Therapeutic ... | FOEHR MATTHEW W | Director | Sell | S | 7.35 | 13,000 | 95,550 | 26,250 | 39.3 K to 26.3 K (-33.12 %) |
| Apr 03 2020 | VKTX | Viking Therapeutic ... | MORNEAU MICHAEL | VP, Finance and Adm ... | Option Exercise | A | 4.68 | 15,000 | 70,200 | 15,000 | |
| Jan 21 2020 | VKTX | Viking Therapeutic ... | Lian Brian | President & CEO | Payment of Exercise | F | 7.18 | 3,195 | 22,940 | 1,704,312 | 1.7 M to 1.7 M (-0.19 %) |
| Jan 21 2020 | VKTX | Viking Therapeutic ... | MORNEAU MICHAEL | VP, Finance and Adm ... | Payment of Exercise | F | 7.18 | 2,044 | 14,676 | 92,840 | 94.9 K to 92.8 K (-2.15 %) |
| Jan 03 2020 | VKTX | Viking Therapeutic ... | MORNEAU MICHAEL | VP, Finance and Adm ... | Option Exercise | A | 7.77 | 40,000 | 310,800 | 40,000 | |
| Jan 03 2020 | VKTX | Viking Therapeutic ... | Lian Brian | President & CEO | Option Exercise | A | 7.77 | 345,000 | 2,680,650 | 345,000 | |
| Jan 03 2020 | VKTX | Viking Therapeutic ... | Lian Brian | President & CEO | Payment of Exercise | F | 7.77 | 6,782 | 52,696 | 1,707,507 | 1.7 M to 1.7 M (-0.40 %) |
| Jan 03 2020 | VKTX | Viking Therapeutic ... | Lian Brian | President & CEO | Grant | A | 0.00 | 153,333 | 0 | 1,714,289 | 1.6 M to 1.7 M (+9.82 %) |
| Jan 03 2020 | VKTX | Viking Therapeutic ... | Webster Stephen W | Director | Option Exercise | A | 7.95 | 22,000 | 174,900 | 22,000 | |
| Jan 03 2020 | VKTX | Viking Therapeutic ... | SINGLETON J MATTHEW | Director | Option Exercise | A | 7.95 | 22,000 | 174,900 | 22,000 | |
| Jan 03 2020 | VKTX | Viking Therapeutic ... | FOEHR MATTHEW W | Director | Option Exercise | A | 7.95 | 22,000 | 174,900 | 22,000 | |
| Jan 03 2020 | VKTX | Viking Therapeutic ... | MACARTNEY LAWSON | Director | Option Exercise | A | 7.95 | 22,000 | 174,900 | 22,000 | |
| Jan 03 2020 | VKTX | Viking Therapeutic ... | Rowland Charles A Jr | Director | Option Exercise | A | 7.95 | 22,000 | 174,900 | 22,000 | |
| Jan 03 2020 | VKTX | Viking Therapeutic ... | Rouan Sarah Kathryn | Director | Option Exercise | A | 7.95 | 22,000 | 174,900 | 22,000 | |
| Oct 31 2019 | VKTX | Viking Therapeutic ... | MORNEAU MICHAEL | VP, Finance and Adm ... | Option Exercise | A | 6.47 | 2,500 | 16,175 | 2,500 | |
| Aug 02 2019 | VKTX | Viking Therapeutic ... | MORNEAU MICHAEL | VP, Finance and Adm ... | Option Exercise | A | 7.69 | 7,500 | 57,675 | 7,500 | |
| Jul 02 2019 | VKTX | Viking Therapeutic ... | Rouan Sarah Kathryn | Director | Option Exercise | A | 8.32 | 55,000 | 457,600 | 55,000 | |
| Jan 22 2019 | VKTX | Viking Therapeutic ... | MORNEAU MICHAEL | VP, Finance and Adm ... | Payment of Exercise | F | 8.78 | 2,044 | 17,946 | 91,991 | 94 K to 92 K (-2.17 %) |
| Jan 22 2019 | VKTX | Viking Therapeutic ... | Lian Brian | President & CEO | Payment of Exercise | F | 8.78 | 4,333 | 38,044 | 1,560,152 | 1.6 M to 1.6 M (-0.28 %) |
| Jan 03 2019 | VKTX | Viking Therapeutic ... | MORNEAU MICHAEL | VP, Finance and Adm ... | Option Exercise | A | 7.58 | 29,000 | 219,820 | 29,000 | |
| Jan 03 2019 | VKTX | Viking Therapeutic ... | Masamune Hiroko | Chief Development O ... | Option Exercise | A | 7.58 | 66,000 | 500,280 | 66,000 | |
| Jan 03 2019 | VKTX | Viking Therapeutic ... | Masamune Hiroko | Chief Development O ... | Grant | A | 0.00 | 22,667 | 0 | 141,063 | 118.4 K to 141.1 K (+19.15 %) |
| Jan 03 2019 | VKTX | Viking Therapeutic ... | Lian Brian | President & CEO | Option Exercise | A | 7.58 | 235,554 | 1,785,499 | 235,554 | |
| Jan 03 2019 | VKTX | Viking Therapeutic ... | Lian Brian | President & CEO | Grant | A | 0.00 | 80,897 | 0 | 1,564,485 | 1.5 M to 1.6 M (+5.45 %) |
| Jan 03 2019 | VKTX | Viking Therapeutic ... | Webster Stephen W | Director | Option Exercise | A | 8.32 | 22,000 | 183,040 | 22,000 | |
| Jan 03 2019 | VKTX | Viking Therapeutic ... | SINGLETON J MATTHEW | Director | Option Exercise | A | 8.32 | 22,000 | 183,040 | 22,000 | |
| Jan 03 2019 | VKTX | Viking Therapeutic ... | FOEHR MATTHEW W | Director | Option Exercise | A | 8.32 | 22,000 | 183,040 | 22,000 | |
| Jan 03 2019 | VKTX | Viking Therapeutic ... | MACARTNEY LAWSON | Director | Option Exercise | A | 8.32 | 22,000 | 183,040 | 22,000 | |
| Jan 03 2019 | VKTX | Viking Therapeutic ... | Rowland Charles A Jr | Director | Option Exercise | A | 8.32 | 22,000 | 183,040 | 22,000 | |
| Sep 27 2018 | VKTX | Viking Therapeutic ... | LIGAND PHARMACEUTICALS INC | 10% Owner | Option Exercise | J | 0.00 | 1,916,509 | 0 | 0 | |
| Sep 27 2018 | VKTX | Viking Therapeutic ... | LIGAND PHARMACEUTICALS INC | 10% Owner | Option Exercise | J | 0.00 | 38,630 | 0 | 1,916,509 | |
| Sep 27 2018 | VKTX | Viking Therapeutic ... | LIGAND PHARMACEUTICALS INC | 10% Owner | Sell | S | 19.15 | 262,881 | 5,034,250 | 6,038,083 | 6.3 M to 6 M (-4.17 %) |
| Jul 03 2018 | VKTX | Viking Therapeutic ... | Masamune Hiroko | Chief Development O ... | Option Exercise | A | 9.49 | 42,000 | 398,580 | 42,000 | |
| Jul 03 2018 | VKTX | Viking Therapeutic ... | Masamune Hiroko | Chief Development O ... | Grant | A | 0.00 | 15,000 | 0 | 111,197 | 96.2 K to 111.2 K (+15.59 %) |
| May 31 2018 | VKTX | Viking Therapeutic ... | SINGLETON J MATTHEW | Director | Buy | P | 9.82 | 9,500 | 93,261 | 9,500 | 0 to 9.5 K |
| May 31 2018 | VKTX | Viking Therapeutic ... | MORNEAU MICHAEL | VP, Finance and Adm ... | Sell | S | 9.25 | 21,551 | 199,347 | 94,035 | 115.6 K to 94 K (-18.64 %) |
| May 31 2018 | VKTX | Viking Therapeutic ... | Rowland Charles A Jr | Director | Buy | P | 5.16 | 30,000 | 154,800 | 30,000 | 0 to 30 K |
| May 31 2018 | VKTX | Viking Therapeutic ... | Webster Stephen W | Director | Buy | P | 5.21 | 8,000 | 41,712 | 8,000 | 0 to 8 K |
| May 31 2018 | VKTX | Viking Therapeutic ... | MACARTNEY LAWSON | Director | Buy | P | 5.22 | 47,965 | 250,329 | 47,965 | 0 to 48 K |
| May 08 2018 | VKTX | Viking Therapeutic ... | MORNEAU MICHAEL | VP, Finance and Adm ... | Payment of Exercise | F | 4.22 | 7,616 | 32,140 | 94,035 | 101.7 K to 94 K (-7.49 %) |
| May 08 2018 | VKTX | Viking Therapeutic ... | Lian Brian | President & CEO | Payment of Exercise | F | 4.22 | 10,086 | 42,563 | 1,483,012 | 1.5 M to 1.5 M (-0.68 %) |
| Jan 23 2018 | VKTX | Viking Therapeutic ... | MORNEAU MICHAEL | Chief Financial Off ... | Option Exercise | A | 4.65 | 52,500 | 244,125 | 52,500 | |
| Jan 23 2018 | VKTX | Viking Therapeutic ... | MORNEAU MICHAEL | Chief Financial Off ... | Grant | A | 0.00 | 15,000 | 0 | 101,651 | 86.7 K to 101.7 K (+17.31 %) |
| Jan 23 2018 | VKTX | Viking Therapeutic ... | Lian Brian | President & CEO | Option Exercise | A | 4.65 | 140,000 | 651,000 | 140,000 | |
| Jan 23 2018 | VKTX | Viking Therapeutic ... | Lian Brian | President & CEO | Grant | A | 0.00 | 40,000 | 0 | 1,493,098 | 1.5 M to 1.5 M (+2.75 %) |
| Jan 03 2018 | VKTX | Viking Therapeutic ... | FOEHR MATTHEW W | Director | Option Exercise | A | 4.48 | 16,000 | 71,680 | 16,000 | |
| Jul 05 2017 | VKTX | Viking Therapeutic ... | Rowland Charles A Jr | Director | Option Exercise | A | 1.08 | 40,000 | 43,200 | 40,000 | |
| May 05 2017 | VKTX | Viking Therapeutic ... | MORNEAU MICHAEL | Chief Financial Off ... | Payment of Exercise | F | 1.34 | 8,192 | 10,977 | 80,604 | 88.8 K to 80.6 K (-9.23 %) |
| Jan 05 2017 | VKTX | Viking Therapeutic ... | MORNEAU MICHAEL | Chief Financial Off ... | Option Exercise | A | 1.23 | 17,605 | 21,654 | 17,605 | |
| Jan 05 2017 | VKTX | Viking Therapeutic ... | MORNEAU MICHAEL | Chief Financial Off ... | Option Exercise | A | 1.23 | 95,000 | 116,850 | 95,000 | |
| Jan 05 2017 | VKTX | Viking Therapeutic ... | Lian Brian | President & CEO | Option Exercise | A | 1.23 | 34,931 | 42,965 | 34,931 | |
| Jan 05 2017 | VKTX | Viking Therapeutic ... | Lian Brian | President & CEO | Option Exercise | A | 1.23 | 250,000 | 307,500 | 250,000 | |
| Jan 05 2017 | VKTX | Viking Therapeutic ... | FOEHR MATTHEW W | Director | Option Exercise | A | 1.19 | 16,000 | 19,040 | 16,000 | |
| Jan 05 2017 | VKTX | Viking Therapeutic ... | SINGLETON J MATTHEW | Director | Option Exercise | A | 1.19 | 16,000 | 19,040 | 16,000 | |
| Jan 05 2017 | VKTX | Viking Therapeutic ... | Webster Stephen W | Director | Option Exercise | A | 1.19 | 16,000 | 19,040 | 16,000 | |
| Jan 05 2017 | VKTX | Viking Therapeutic ... | MACARTNEY LAWSON | Director | Option Exercise | A | 1.19 | 16,000 | 19,040 | 16,000 | |
| Nov 15 2016 | VKTX | Viking Therapeutic ... | FOEHR MATTHEW W | Director | Buy | P | 1.21 | 13,000 | 15,678 | 39,250 | 26.3 K to 39.3 K (+49.52 %) |
| May 05 2016 | VKTX | Viking Therapeutic ... | Hanley Rochelle | Chief Medical Offic ... | Payment of Exercise | F | 1.31 | 10,595 | 13,879 | 160,836 | 171.4 K to 160.8 K (-6.18 %) |
| Mar 15 2016 | VKTX | Viking Therapeutic ... | MORNEAU MICHAEL | Chief Financial Off ... | Option Exercise | A | 1.88 | 19,934 | 37,476 | 19,934 | |
| Mar 15 2016 | VKTX | Viking Therapeutic ... | Lian Brian | President & CEO | Option Exercise | A | 1.88 | 54,336 | 102,152 | 54,336 | |
| Mar 08 2016 | VKTX | Viking Therapeutic ... | Hanley Rochelle | Chief Medical Offic ... | Option Exercise | A | 2.15 | 35,250 | 75,788 | 35,250 | |
| Mar 08 2016 | VKTX | Viking Therapeutic ... | MORNEAU MICHAEL | Chief Financial Off ... | Option Exercise | A | 2.15 | 40,000 | 86,000 | 40,000 | |
| Mar 08 2016 | VKTX | Viking Therapeutic ... | Lian Brian | President & CEO | Option Exercise | A | 2.15 | 125,000 | 268,750 | 125,000 | |
| Apr 15 2016 | VKTX | Viking Therapeutic ... | LIGAND PHARMACEUTICALS INC | 10% Owner | Option Exercise | J | 0.00 | 150,000 | 0 | 1,955,139 | |
| Apr 15 2016 | VKTX | Viking Therapeutic ... | LIGAND PHARMACEUTICALS INC | 10% Owner | Option Exercise | C | 1.50 | 960,000 | 1,440,000 | 1,520,000 | |
| Apr 15 2016 | VKTX | Viking Therapeutic ... | LIGAND PHARMACEUTICALS INC | 10% Owner | Option Exercise | C | 0.00 | 600,000 | 0 | 2,105,139 | |
| Apr 15 2016 | VKTX | Viking Therapeutic ... | LIGAND PHARMACEUTICALS INC | 10% Owner | Option Exercise | A | 1.50 | 560,000 | 840,000 | 560,000 | |
| Apr 15 2016 | VKTX | Viking Therapeutic ... | LIGAND PHARMACEUTICALS INC | 10% Owner | Buy | C | 1.25 | 960,000 | 1,200,000 | 6,300,964 | 5.3 M to 6.3 M (+17.97 %) |
| Apr 15 2016 | VKTX | Viking Therapeutic ... | LIGAND PHARMACEUTICALS INC | 10% Owner | Grant | A | 0.00 | 560,000 | 0 | 5,340,964 | 4.8 M to 5.3 M (+11.71 %) |
| Apr 13 2016 | VKTX | Viking Therapeutic ... | FOEHR MATTHEW W | Director | Option Exercise | P | 1.50 | 20,000 | 30,000 | 20,000 | |
| Apr 13 2016 | VKTX | Viking Therapeutic ... | FOEHR MATTHEW W | Director | Buy | P | 1.24 | 20,000 | 24,800 | 26,250 | 6.3 K to 26.3 K (+320.00 %) |
| Jan 06 2016 | VKTX | Viking Therapeutic ... | Webster Stephen W | Director | Option Exercise | A | 3.33 | 16,000 | 53,280 | 16,000 | |
| Jan 06 2016 | VKTX | Viking Therapeutic ... | SINGLETON J MATTHEW | Director | Option Exercise | A | 3.33 | 16,000 | 53,280 | 16,000 | |
| Jan 06 2016 | VKTX | Viking Therapeutic ... | FOEHR MATTHEW W | Director | Option Exercise | A | 3.33 | 16,000 | 53,280 | 16,000 | |
| Jan 06 2016 | VKTX | Viking Therapeutic ... | MACARTNEY LAWSON | Director | Option Exercise | A | 3.33 | 16,000 | 53,280 | 16,000 | |
| Jun 01 2015 | VKTX | Viking Therapeutic ... | LIGAND PHARMACEUTICALS INC | 10% Owner | Buy | J | 0.00 | 228,105 | 0 | 4,780,964 | 4.6 M to 4.8 M (+5.01 %) |
| May 06 2015 | VKTX | Viking Therapeutic ... | Lian Brian | President & CEO | Option Exercise | A | 9.49 | 87,500 | 830,375 | 87,500 | |
| May 06 2015 | VKTX | Viking Therapeutic ... | Lian Brian | President & CEO | Payment of Exercise | F | 9.49 | 16,346 | 155,124 | 1,453,098 | 1.4 M to 1.5 M (+1.14 %) |
| May 06 2015 | VKTX | Viking Therapeutic ... | Lian Brian | President & CEO | Buy | C | 0.00 | 9,927 | 0 | 1,436,752 | 1.4 M to 1.4 M (+0.70 %) |
| May 06 2015 | VKTX | Viking Therapeutic ... | Lian Brian | President & CEO | Buy | C | 0.00 | 2,731 | 0 | 1,426,825 | 1.4 M to 1.4 M (+0.19 %) |
| May 06 2015 | VKTX | Viking Therapeutic ... | Lian Brian | President & CEO | Grant | A | 0.00 | 87,500 | 0 | 1,424,094 | 1.3 M to 1.4 M (+6.55 %) |
| May 06 2015 | VKTX | Viking Therapeutic ... | Lian Brian | President & CEO | Sell | D | 0.00 | 2,313,406 | 0 | 1,336,594 | 3.7 M to 1.3 M (-63.38 %) |
| May 06 2015 | VKTX | Viking Therapeutic ... | Dinerman Michael | Chief Operating Off ... | Option Exercise | A | 9.49 | 45,000 | 427,050 | 45,000 | |
| May 06 2015 | VKTX | Viking Therapeutic ... | Dinerman Michael | Chief Operating Off ... | Payment of Exercise | F | 9.49 | 8,724 | 82,791 | 694,116 | 685.4 K to 694.1 K (+1.27 %) |
| May 06 2015 | VKTX | Viking Therapeutic ... | Dinerman Michael | Chief Operating Off ... | Buy | C | 0.00 | 3,642 | 0 | 685,392 | 681.8 K to 685.4 K (+0.53 %) |
| May 06 2015 | VKTX | Viking Therapeutic ... | Dinerman Michael | Chief Operating Off ... | Grant | A | 0.00 | 105,000 | 0 | 681,750 | 576.8 K to 681.8 K (+18.21 %) |
| May 06 2015 | VKTX | Viking Therapeutic ... | Dinerman Michael | Chief Operating Off ... | Sell | D | 0.00 | 998,250 | 0 | 576,750 | 1.6 M to 576.8 K (-63.38 %) |
| May 06 2015 | VKTX | Viking Therapeutic ... | MORNEAU MICHAEL | Chief Financial Off ... | Option Exercise | A | 9.49 | 25,500 | 241,995 | 25,500 | |
| May 06 2015 | VKTX | Viking Therapeutic ... | MORNEAU MICHAEL | Chief Financial Off ... | Payment of Exercise | F | 9.49 | 10,404 | 98,734 | 77,404 | 67 K to 77.4 K (+15.53 %) |
| May 06 2015 | VKTX | Viking Therapeutic ... | MORNEAU MICHAEL | Chief Financial Off ... | Grant | A | 0.00 | 67,000 | 0 | 67,000 | 0 to 67 K |
| May 06 2015 | VKTX | Viking Therapeutic ... | Hanley Rochelle | Chief Medical Offic ... | Option Exercise | A | 9.49 | 30,000 | 284,700 | 30,000 | |
| May 06 2015 | VKTX | Viking Therapeutic ... | Hanley Rochelle | Chief Medical Offic ... | Payment of Exercise | F | 9.49 | 7,308 | 69,353 | 168,855 | 161.5 K to 168.9 K (+4.52 %) |
| May 06 2015 | VKTX | Viking Therapeutic ... | Hanley Rochelle | Chief Medical Offic ... | Grant | A | 0.00 | 70,000 | 0 | 161,547 | 91.5 K to 161.5 K (+76.46 %) |
| May 06 2015 | VKTX | Viking Therapeutic ... | Hanley Rochelle | Chief Medical Offic ... | Sell | D | 0.00 | 158,453 | 0 | 91,547 | 250 K to 91.5 K (-63.38 %) |
| May 05 2015 | VKTX | Viking Therapeutic ... | FOEHR MATTHEW W | Director | Buy | P | 8.00 | 6,250 | 50,000 | 6,250 | 0 to 6.3 K |
| Apr 30 2015 | VKTX | Viking Therapeutic ... | Webster Stephen W | Director | Option Exercise | A | 8.00 | 20,786 | 166,288 | 20,786 | |
| Apr 30 2015 | VKTX | Viking Therapeutic ... | MACARTNEY LAWSON | Director | Option Exercise | A | 8.00 | 20,786 | 166,288 | 20,786 | |
| Apr 30 2015 | VKTX | Viking Therapeutic ... | FOEHR MATTHEW W | Director | Option Exercise | A | 8.00 | 20,786 | 166,288 | 20,786 | |
| Apr 30 2015 | VKTX | Viking Therapeutic ... | SINGLETON J MATTHEW | Director | Option Exercise | A | 8.00 | 20,786 | 166,288 | 20,786 |
Page: 1